Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab

被引：0
|
作者：
Cioppa, Vittoria [1 ]
Lazzeri, Laura [1 ]
Carraro, Andrea [1 ]
De Piano, Ernesto [1 ]
Falcinelli, Francesca [1 ]
Galluzzo, Marco [2 ]
Pallotta, Sabatino [3 ]
De Pita, Ornella [3 ]
Russo, Filomena [3 ]
机构：
[1] Univ Siena, S Maria Scotte Hosp, Dept Med Surg & Neurol Sci, Dermatol Sect, Siena, Italy
[2] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy
[3] Dermatol Res Hosp, IDI IRCCS, Rome, Italy
来源：
DERMATITIS | 2024年 / 35卷
关键词：
D O I：
10.1089/derm.2023.0052
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis
    Nettis, Eustachio
    Patella, Vincenzo
    Lombardo, Carla
    Detoraki, Aikaterini
    Macchia, Luigi
    Di Leo, Elisabetta
    Carbonara, Monica
    Canonica, Giorgio W.
    Bonzano, Laura
    ALLERGY, 2020, 75 (10) : 2653 - 2661
  • [22] Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China
    Song, Xiaoting
    Liu, Bo
    Luan, Tingting
    Liao, Shuanglu
    Tan, Yen
    Peng, Chengyue
    Zhao, Zuotao
    ALLERGY, 2023, 78 (06) : 1696 - 1699
  • [23] Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children
    Parker, Jennifer J.
    Sugarman, Jeffrey L.
    Silverberg, Nanette B.
    Gonzalez, Mercedes Elena
    Ramien, Michele L.
    Teng, Joyce M. C.
    Paller, Amy S.
    PEDIATRIC DERMATOLOGY, 2021, 38 (06) : 1500 - 1505
  • [24] Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis
    Cork, Michael
    Beck, Lisa
    Bissonnette, Robert
    Wollenberg, Andreas
    Simpson, Eric
    Praestgaard, Amy
    Aamodt, Kimberly
    Rossi, Ana
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 69 - 69
  • [25] Treatment satisfaction with long-term dupilumab treatment in adult patients with moderate-to-severe atopic dermatitis (LIBERTY AD OLE)
    Thaci, D.
    Blauvelt, A.
    Hussain, I
    Bastian, M.
    Sun, X.
    Chao, J.
    Levit, N. A.
    Rossi, A. B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 65 - 65
  • [26] COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
    Ungar, Benjamin
    Glickman, Jacob W.
    Golant, Alexandra K.
    Dubin, Celina
    Marushchak, Olga
    Gontzes, Alyssa
    Mikhaylov, Daniela
    Singer, Giselle K.
    Baum, Danielle
    Wei, Nancy
    Sanin, Antonio
    Gruenstein, Diana
    Lebwohl, Mark G.
    Pavel, Ana B.
    Guttman-Yassky, Emma
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (01): : 134 - 142
  • [27] Long-term Dupilumab treatment up to 100 weeks reduces serum biomarkers in patients with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Bissonette, Robert
    Deleuran, Mette
    Harel, Sivan
    McDonald, Robert
    Shumel, Brad
    Rossi, Ana B.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 168 - 168
  • [28] Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients
    Dal Bello, Giacomo
    Maurelli, Martina
    Schena, Donatella
    Girolomoni, Giampiero
    Gisondi, Paolo
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [29] DUPILUMAB TREATMENT RAPIDLY IMPROVES ITCH IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Silverberg, J.
    Chao, J.
    Eckert, L.
    Chen, Z.
    Ardeleanu, M.
    Shumel, B.
    Plaum, S.
    Graham, N.
    Pirozzi, G.
    Gadkari, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S95 - S95
  • [30] Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate-to-severe atopic dermatitis
    Staumont-Salle, Delphine
    Barbarot, Sebastien
    Bouaziz, Jean David
    Chan, Chan
    Clibborn, Claire
    Du-Thanh, Aurelie
    Feeney, Claire
    Lejeune, Alexandre
    Misery, Laurent
    Nosbaum, Audrey
    Seneschal, Julien
    Soria, Angele
    Zhang, Fan
    JEADV CLINICAL PRACTICE, 2023, 2 (03): : 518 - 530
12345